^
    Back
    Association details:
    Biomarker:VEGFA elevation
    Cancer:Hepatocellular Cancer
    Drug Class:T-lymphocyte cell therapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Oncoimmunology
    Title:

    Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial

    Published date:
    11/25/2020
    Excerpt:
    This phase II study investigated CD133-directed chimeric antigen receptor (CAR) T (CART-133) cells in adults with HCC….a higher VEGF level was significantly correlated with a longer OS and PFS…
    DOI:
    10.1080/2162402X.2020.1846926
    Trial ID:
    NCT02541370